M6P Therapeutics is a privately held, venture-backed platform company developing the next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs). Our breakthrough technology markedly enhances the mannose 6-phosphate content on lysosomal enzymes, which improves enzyme uptake to target tissues leading to improved efficacy. This can translate to multiple value drivers: more efficacious treatments, lower dosing, reduced immunogenicity and less frequent dosing regimens. Using the core technology, we created a generalized “bicistronic platform” that can work with any lysosomal enzyme for both ERT and Gene Tx modalities. We have promising data across numerous programs, and our drug candidates hold a strong promise of becoming the best-in-class LSD treatments by improving patient outcomes and addressing remaining unmet needs.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):